{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-006360","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.965069+00:00","generated_at":"2026-05-30T00:36:06.901988+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MiNK Therapeutics Q3 2024 net loss narrows to $1.8M; cash at $6.3M","bullets":["Net loss of $1.8M ($0.05 per share) improved from $5.1M ($0.15) in Q3 2023.","Cash and equivalents $6.3M; operations used $3.0M in Q3, down from $4.2M YoY.","R&D expenses fell to $541K from $3.4M; total operating loss $1.9M vs $5.2M.","Phase 2 gastric cancer trial data expected at a major conference in early 2025.","Dr. Robert Kadlec joined board; new collaboration with Autonomous Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-006360","json":"https://secwatch.observer/filing/0001171843-24-006360.json","markdown":"https://secwatch.observer/filing/0001171843-24-006360.md","text":"https://secwatch.observer/filing/0001171843-24-006360.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000117184324006360/0001171843-24-006360-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000117184324006360/f8k_111424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:36:06.901988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}